Robert E. Coleman
YOU?
Author Swipe
View article: Demographics of epithelioid trophoblastic tumour and placental site trophoblastic tumour: a 21 year UK population study
Demographics of epithelioid trophoblastic tumour and placental site trophoblastic tumour: a 21 year UK population study Open
ETT and PSTT are both rare diagnoses with little detailed information on their demographics. The data in this study indicates a wide range in the interval from the antecedent pregnancy to diagnosis and confirms a close relationship between…
View article: Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: An updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG
Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: An updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG Open
Current published literature, including recent clinical trial reports, systematic reviews and meta-analyses, continue to affirm the high risk of fractures in women with breast cancer who are receiving adjuvant AI treatment, a risk which ha…
View article: Prolonged bone health benefits for breast cancer patients following adjuvant bisphosphonate therapy: the BoHFAB study
Prolonged bone health benefits for breast cancer patients following adjuvant bisphosphonate therapy: the BoHFAB study Open
Adjuvant bisphosphonates are often recommended in postmenopausal women with early breast cancer at intermediate-to-high risk of disease recurrence, but the magnitude and duration of their effects on bone mineral density (BMD) and bone turn…
View article: Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials
Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials Open
Background Most women with advanced breast cancer have skeletal metastases. Radium-223 is an alpha-emitting radionuclide that selectively targets areas of bone metastases. Methods Two double-blind, placebo-controlled studies of radium-223 …
View article: Supplementary Figures and Table Legends from Modulating Bone Marrow Hematopoietic Lineage Potential to Prevent Bone Metastasis in Breast Cancer
Supplementary Figures and Table Legends from Modulating Bone Marrow Hematopoietic Lineage Potential to Prevent Bone Metastasis in Breast Cancer Open
Supplementary Figures and Table Legends to support primary figures
View article: Supplementary figure 3 from Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment
Supplementary figure 3 from Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment Open
Incubation with high concentrations of exogenous IL-1B modestly increases tumour cell migration and invasion.
View article: Data from Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER<sup>+</sup> Invasive Breast Cancer (STAKT)
Data from Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER<sup>+</sup> Invasive Breast Cancer (STAKT) Open
Purpose:The STAKT study examined short-term exposure (4.5 days) to the oral selective pan-AKT inhibitor capivasertib (AZD5363) to determine if this drug can reach its therapeutic target in sufficient concentration to significantly modulate…
View article: Supplementary table 1 from Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment
Supplementary table 1 from Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment Open
Tumour-derived IL-1B predicts distant recurrence and relapse in bone in patients with stage II and III breast cancer.
View article: Supplementary figure 4 from Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment
Supplementary figure 4 from Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment Open
Isolation of circulating tumour cells from mice treated with IL-1Ra or Canakinumab
View article: Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT Open
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. …
View article: Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials
Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials Open
Background Most women with advanced breast cancer have skeletal metastases. Radium-223 is an alpha-emitting radionuclide that selectively targets areas of bone metastases. Methods Two double-blind, placebo-controlled studies of radium-223 …
View article: Bone-Targeted Agents and Metastasis Prevention
Bone-Targeted Agents and Metastasis Prevention Open
The use of bone-targeted treatments has transformed the clinical care of many patients with metastatic breast cancer. In addition, due to the profound effects of bisphosphonates and denosumab on bone physiology and the bone microenvironmen…
View article: POSNOC—POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy: a randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes
POSNOC—POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy: a randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes Open
Introduction ACOSOG-Z0011(Z11) trial showed that axillary node clearance (ANC) may be omitted in women with ≤2 positive nodes undergoing breast conserving surgery (BCS) and whole breast radiotherapy (RT). A confirmatory study is needed to …
View article: Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer
Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer Open
ClinicalTrials.gov Identifier: NCT02429427 and isrctn.org Identifier: ISRCTN48254013.
View article: Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment
Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment Open
ClinicalTrials.gov Identifier: NCT02181101.
View article: Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial
Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial Open
Background Anastrozole has been associated with substantial accelerated bone mineral density (BMD) loss during active treatment. Methods One thousand four hundred and ten women were included in a BMD substudy and stratified into three stra…
View article: Individualized Bone-Protective Management in Long-Term Cancer Survivors With Bone Metastases
Individualized Bone-Protective Management in Long-Term Cancer Survivors With Bone Metastases Open
Antiresorptive therapy is an important component of a multimodal approach to treating patients with advanced malignancies and metastatic bone disease. Over the past decade, overall survival of affected patients has improved in most cancer …
View article: Bone health in cancer: ESMO Clinical Practice Guidelines
Bone health in cancer: ESMO Clinical Practice Guidelines Open
The clinical course of advanced cancer for many patients with bone metastases can be transformed through optimum multidisciplinary management. • Bone-targeted agents significantly reduce skeletal morbidity in patients with bone metastases …